<DOC>
	<DOCNO>NCT02599064</DOCNO>
	<brief_summary>This study design evaluate safety , tolerability clinical activity RXI-109 administer intravitreal injection reduce progression subretinal fibrosis subject advance neovascular age-related macular degeneration ( NVAMD ) .</brief_summary>
	<brief_title>Evaluating RXI-109 Reduce Progression Subretinal Fibrosis Subjects With NVAMD</brief_title>
	<detailed_description>Evaluate safety , tolerability pharmacokinetics ( PK ) single multiple dos RXI-109 administer intravitreal injection . Evaluate clinical activity single multiple dos RXI-109 administer intravitreal injection . Study participation intend seven month time initial treatment RXI-109 .</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Choroidal Neovascularization</mesh_term>
	<mesh_term>Neovascularization , Pathologic</mesh_term>
	<mesh_term>Cicatrix</mesh_term>
	<criteria>Subjects present advanced NVAMD study eye BCVA ≤20/100 potentially due subretinal fibrosis involve fovea BCVA ≥20/800 contralateral eye well study eye ≥50 year age Subfoveal choroidal neovascularization ( CNV ) type Presence cause CNV include pathologic myopia , ocular histoplasmosis syndrome , angioid streak , choroidal rupture , multifocal choroiditis Evidence inflammation ( Grade 1 high ) anterior posterior chamber</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Age-related macular degeneration</keyword>
	<keyword>RXI-109</keyword>
	<keyword>NVAMD</keyword>
	<keyword>Retinal scarring</keyword>
	<keyword>Subretinal scarring</keyword>
	<keyword>Retinal fibrosis</keyword>
	<keyword>Subretinal fibrosis</keyword>
	<keyword>Eye disease</keyword>
</DOC>